

RENAISSANCE GLOBAL HEALTH CARE FUND

*As at June 30, 2023

Investment objective

Renaissance Global Health Care Fund seeks to obtain long-term capital appreciation by investing primarily in U.S. companies and global companies with U.S. operations, or exposure to U.S. markets, or whose securities are traded on a U.S. exchange, which are engaged in the design, development, manufacturing, and distribution of products or services in the health care sectors. The Fund will invest in a diversified portfolio, which will mainly include securities in the medical technology, biotechnology, health care, and pharmaceutical sectors.

Profile

Fund category	Sector equity
Inception date	January 2, 2001 (Series O)
Investment style	Bottom-up, quality
Risk tolerance	Medium
Strategy AUM	\$760.1 M

Why invest in this fund?

- Capitalize on growing global health care expenditure and innovation
- Aims to significantly outperform over the long
- Uses an informational edge to invest in innovative high-quality companies
- Expertise in scientific research, clinical medicine, and finance

Investment philosophy

A bottom-up, fundamental approach that uses and informational edge to invest in innovative, high-quality companies over the long term, underpinned by strong risk management capabilities.

High-quality companies	 Global innovation leaders Measuring return on invested capital, leverage and volatility Seeking management teams with strong track records
Long-term focus	 Strategic holdings based on a 3-to-5-year outlook Tactical holdings based on 12-to-18-month outlook
Informational edge	Understanding key scientific, medical, regulator and economic trends affecting the global healthcare industry
Risk management	A "capital preservation first" approachMultivariate scenario analysis

Performance (%) *As at June 30, 2023

Trailing returns	3 МО	YTD	1 YF	₹	3 YR	5 YR	10 YR	Since in	ception
Renaissance Global Health Care Fund - Series O	0.9	0.6	9.6		4.6	8.3	13.7	10).3
MSCI World Health Care Index	0.3	(1.3)	9.6		8.0	10.7	13.4	(4	.1)
Calendar year returns	2022	2021	2020	2019	2018	2017	2016	2015	2014
Renaissance Global Health Care Fund - Series O	(4.1)	11.5	12.4	19.9	10.0	8.5	(10.8)	35.2	38.5

CIBC portfolio manager inception: September 2022

Top ten holdings

Holding	%
Johnson & Johnson	9.5
Roche Holdings	7.9
UnitedHealth Group	7.3
Novartis	6.8
Thermo Fisher Scientific	6.4
Medtronic	6.0
Pfizer	5.8
Sanofi	5.5
IQVIA Holdings	5.3
CVS Health	5.0

Equity characteristics

Characteristic	Portfolio	Benchmark
Price-to-Book	3.1	4.3
Price/Equity Trailing 12 month	38.0	26.5
Price/Equity Forecast 12 month	18.2	17.8
Return on Equity (Annual)	11.1	17.1
Earnings Per Share (3 year annual growth)	0.2	11.8
Earnings Per Share (Historical 5 year)	9.1	12.0
Active share	63.5%	N/A
Dividend yield	2.4	1.8

Sector allocation (% of assets)*



Portfolio management



Michal Marszal, CFA

Portfolio Manager, Equities — Global Healthcare

Michal Marszal is a Portfolio Manager with Equities - Global Healthcare at CIBC Asset Management and is responsible for research coverage and stock selection within the global healthcare sector. Prior to joining CIBC in 2017, Mr. Marszal was a consultant in healthcare equity research for Caisse de dépôt et placement du Québec. Previously, he was a senior analyst focusing on healthcare therapeutics at Lombard Odier Investment Managers. Mr. Marszal began his investment career as an analyst covering medical technology, and subsequently biotechnology companies at Sectoral Asset Management.

Mr. Marszal holds a Doctor of Medicine and Master of Surgery degree from McGill University. Upon graduating from medical school, he joined the Neurological Surgery Residency training program at Stanford University Medical Center as a resident physician. Mr. Marszal also holds an MBA degree in Finance from McGill University and a Bachelor of Arts degree in Molecular Biology from Bard College. He is a CFA charterholder and member of the CFA Society of Toronto.

Portfolio positioning

- The Renaissance Global Health Care Fund outperformed its benchmark over 3-months
- The Fund outperforms over all major timeframes since our PM inception date in September 2022, including 3-months and YTD
- Portfolio turnover remains at historical norms with one new buy, and three outright liquidations from the portfolio
- Intuitive Surgical and IQIVIA were the top contributors to performance throughout the most recent quarter
- Thermo Fisher Scientific and Merck were the largest detractors from Fund performance
- Within the health care sector, we continue to remain defensive and cautiously optimistic
- The portfolio has fairly balanced exposure across the three major health care sub-sectors in pharmaceuticals, medical technology, and health care services
- Within each of the major sub-sectors, we've shifted our exposures to the least economically sensitive areas, and towards ones that are durable, long-term oriented and have less interest rate risk

*Totals may not equal 100% due to rounding.

Source: CIBC Asset Management, Refinitiv Eikon. Series O performance is presented gross of fees.

Renaissance Investments is offered by CIBC Asset Management Inc. The views expressed in this document are the views of CIBC Asset Management Inc. and are subject to change at any time. CIBC Asset Management Inc. does not undertake any obligation or responsibility to update such opinions. This document is provided for general informational purposes only and does not constitute financial, investment, tax, legal or accounting advice, it should not be relied upon in that regard or be considered predictive of any future market performance, nor does it constitute an offer or solicitation to buy or sell any securities referred to. Individual circumstances and current events are critical to sound investment planning; anyone wishing to act on this document should consult with his or her advisor. All opinions and estimates expressed in this document are as of the date of publication unless otherwise indicated, and are subject to change. Any information or discussion about the current characteristics of this fund or how the portfolio manager is managing the fund that is supplementary to information in the prospectus is not a discussion about material investment objectives or strategies, but solely a discussion of the current characteristics or manner of fulfilling the investment objectives and strategies, and is subject to change without notice. You should not act or rely on the information without seeking the advice of a professional. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the simplified prospectus before investing. To obtain a copy of the Renaissance Investments family of funds simplified prospectus, call 1-888-888-FUND (3863). Alternatively, you may obtain a copy from your advisor. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. The indicated rates of return are the historical annual compounded total returns as at the date indicated including changes in unit value and reinvestment of all distributions, but do not take into account sales, redemption, distribution or optional charges or income taxes payable by any unitholder that would have reduced returns.

Certain information that we have provided to you may constitute "forward-looking" statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results or achievements to be materially different than the results, performance or achievements expressed or implied in the forwardlooking statements.

®Renaissance Investments is a registered trademark of CIBC Asset Management Inc.

CIBC Asset Management and the CIBC logo are trademarks of Canadian Imperial Bank of Commerce (CIBC), used under license.

The material and/or its contents may not be reproduced without the express written consent of CIBC Asset Management Inc.